Particle.news

Download on the App Store

Savara Securities Suit Deadline Nears as Investor Firms Urge Action

The case stems from the FDA's refusal to file the MOLBREEVI application over missing CMC data.

Overview

  • Faruqi & Faruqi, Kirby McInerney, and Rosen Law Firm issued fresh notices urging Savara investors to seek lead-plaintiff appointment by November 7, 2025.
  • Attorneys say a federal securities class action has been filed covering purchases from March 7, 2024 through May 23, 2025.
  • Savara disclosed on May 27, 2025 that the FDA refused to file its MOLBREEVI Biologics License Application, citing an incomplete submission and requests for additional CMC data.
  • Savara shares fell $0.90, or 31.69%, to close at $1.94 on May 27, 2025 following the disclosure.
  • The complaint alleges misleading statements about the BLA’s completeness, timing, and capital needs, and notices emphasize that no class has been certified and no lead plaintiff has been appointed.